GlassScriptPhysician profile
Clista Dean
NPI 1467811695
$1,783.47
in general payments reported to CMS, 2019-2025
21 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $373 · 2023: $588 · 2024: $526 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,410.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $395.87 | 2022-2025 | |
| Novo Nordisk INC | $199.98 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $197.49 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $194.07 | 2022-2025 | |
| Dexcom, INC. | $120.64 | 2023-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $110.05 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Abbott Laboratories | $90.96 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $66.22 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $63.76 | 2022-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $56.63 | 2024 | Voquezna |
| Pfizer INC. | $47.15 | 2023-2025 | |
| Astellas Pharma US INC | $41.68 | 2024 | Veozah |
| Dynavax Technologies Corporation | $33.88 | 2024 | Heplisav-B |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.81 | 2023-2025 | Xifaxan, Trulance |
| Amgen INC. | $28.25 | 2024 | Repatha, Otezla |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $20.97 | 2023 | Vyjuvek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.93 | 2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $17.69 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.52 | 2024 | Rexulti |
| Scynexis, INC. | $15.55 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.37 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clista Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.